PARADIGM
Financiado
Patients Active in Research and Dialogues for an Improved Generation of Medicine...
Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes.
PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed pro...
PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the ‘return on the engagement’ for all players. Much needed processes and tools for three key decision-making points (research priority setting, design of clinical trials and early dialogue) will be developed by consensus. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a stakeholder-tailored set of metrics to measure the impact of PE.
PARADIGM will deliver to the community, recommendations and tools to support the implementation of PE, leveraging pre-existing resources. These will address capacity and capability questions, managing potential conflict of interest, the compensation of individuals and organisations, and the ethics of engagement. A targeted communication, dissemination and engagement strategy will promote the endorsement of the outputs for their integration in existing structures.
PARADIGM will develop a strategy for sustaining the long-term implementation of PE resources aimed at structuring and supporting the community. This will be a game-changer, addressing fundamental gaps and creating real assets to ensure the sustainability of the PE ecosystem in the years to come.
PARADIGM has a common vision and values-base, and is a highly innovative, consensus-oriented, and experienced consortium, comprising pan-European leaders in patient engagement, academia, SMEs, health professionals, pharmaceutical and biotech companies, pharmaceutical corporate associations, and representatives of competent authorities, all bringing complementary know-how to partner with industry, and a strong commitment to transform patient engagement in Europe.
ver más
Duración del proyecto: 29 meses
Fecha Inicio: 2018-06-04
Fecha Fin: 2020-11-30
Fecha Fin: 2020-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
IMI2-2016-10-07:
Patient perspectives in medicines lifecycle
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
9M€
Líder del proyecto
FORUM DES PATIENTS EUROPEENS
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
90.63K€ |
Participante
181.09K€ |
Participante
413.27K€ |
Participante